| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 357 |
| 1 | ATEZOLIZUMAB | 187 |
| 2 | LENVATINIB | 181 |
| 3 | RIVAROXABAN | 156 |
| 4 | NIVOLUMAB | 155 |
| 5 | PEMBROLIZUMAB | 147 |
| 6 | PACLITAXEL | 134 |
| 7 | APIXABAN | 126 |
| 8 | PACLITAXEL (AIBUMIN-BOUND) | 115 |
| 9 | CISPLATIN | 113 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 485 |
| 1 | Kinase Inhibitor [EPC] | 429 |
| 2 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 366 |
| 3 | Platinum-based Drug [EPC] | 281 |
| 4 | Factor Xa Inhibitor [EPC] | 280 |
| 5 | Nonsteroidal Anti-inflammatory Drug [EPC] | 215 |
| 6 | Microtubule Inhibitor [EPC] | 180 |
| 7 | Corticosteroid [EPC] | 178 |
| 8 | Nucleoside Metabolic Inhibitor [EPC] | 169 |
| 9 | Alkylating Drug [EPC] | 147 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 81 | 0.0128 |
| 1 | Protease Activator [EPC] | 1 | 0.0078 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 485 | 0.0049 |
| 3 | Actinomycin [EPC] | 10 | 0.0045 |
| 4 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 2 | 0.0033 |
| 5 | Vitamin B6 Analog [EPC] | 1 | 0.0028 |
| 6 | Gamma Secretase Inhibitor [EPC] | 2 | 0.0022 |
| 7 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 366 | 0.0020 |
| 8 | Osmotic Diuretic [EPC] | 9 | 0.0017 |
| 9 | CTLA-4-directed Blocking Antibody [EPC] | 77 | 0.0016 |